In Ohio, a state agency says it can't cover GLP-1s for adult obesity even if it wanted to. The reason is one line in its own rulebook. And a rulebook can be rewritten. Somebody just has to decide to. This is GLP-1 Daily, and it's Tuesday, November 3. We start with that Ohio Medicaid fight. Next, a big health-records study comparing GLP-1s with metformin in people with prediabetes, with some important caveats. And Australia's regulator has signed off on the Wegovy pill.
From the Dayton Daily News:
The Ohio Department of Medicaid is prohibited from covering GLP-1 medications specifically for the condition of obesity in adults due to a restriction in the Ohio administrative code, but a national organization is advocating for state officials to change this.
The paper ran this Monday. The group pushing is the Obesity Action Coalition, a national nonprofit. Ohio Medicaid's own statement says that because the exclusion sits in the administrative code, it cannot simply start covering these drugs under current policy. So what is covered? Ohio Medicaid says it pays for certain GLP-1s for type 2 diabetes and some other FDA-approved uses: cardiovascular risk reduction, obstructive sleep apnea, and the liver disease MASH, when its criteria are met. It also covers them for kids under eighteen, because federal law requires Medicaid to cover medically necessary care for minors. Changing it takes either formal rulemaking, reviewed by a legislative panel called the Joint Committee on Agency Rule Review, or a new law from the legislature. Here's what gets me. Same drug, same patient. With a diabetes code on the chart, you're covered. Turn eighteen without one, and you lose it. Nobody forgot to write that rule down. Someone wrote it. And Ohio has company. Citing KFF, the paper says that as of early 2026 only 13 state Medicaid programs cover these drugs for chronic weight management under fee-for-service. California, New Hampshire, Pennsylvania and South Carolina covered them in 2025 and then dropped that coverage, which KFF says likely reflects tight state budgets. And the spending is real: KFF found Medicaid's gross GLP-1 spending went from about one billion dollars in 2019 to almost nine billion in 2024.There is a federal route, too. Under CMS's BALANCE model, CMS negotiates GLP-1 prices and coverage terms with manufacturers for state Medicaid agencies, and states can join through January 1, 2027. If you're on Medicaid in Ohio or anywhere else, ask your prescriber which diagnoses on your chart might qualify you under your state's rules, and ask your plan directly what it covers. Don't count on a headline to tell you.
From the American Heart Association, in a news release issued Monday:
GLP-1 (glucagon-like peptide-1 receptor agonists) medications, currently popular for weight-loss, may help prevent Type 2 diabetes and lower the risk of heart attack and stroke more than the standard diabetes prevention medication metformin among people with prediabetes, according to new, independent, preliminary research presented at the American Heart Association’s Scientific Sessions 2026.
Let's grade the evidence before the numbers. This is a research abstract for a meeting that runs Friday, November 6, through Monday, November 9, in Chicago. The AHA says plainly that abstracts aren't peer reviewed and the findings are preliminary. It's observational, from health records, so it can't prove cause and effect. It is big, though. The team, led by a Mayo Clinic research fellow in Arizona, looked at the records of 256,492 adults with prediabetes and obesity, roughly half on a GLP-1 and half on metformin, matched on age, other conditions and medications. Average follow-up was about three years. Compared with metformin, the GLP-1 group had about a one-and-a-half times higher chance of getting blood sugar back to normal, a 31 percent lower risk of developing type 2 diabetes, and a 41 percent lower risk of dying from any cause. Heart attacks were 15 percent lower, strokes 20 percent, heart failure 25 percent. A 41 percent drop in deaths from any cause in a records study. That's the number I'd hold loosest. The authors list their own limits. Diagnosis codes can be incomplete, prescription records don't show whether people actually took the drug or at what dose, and four different drugs were lumped together. On funding, the release points readers to the abstract for disclosures and funding sources. The study author, Vinicius Serra, also says metformin is still a first-line choice, safe and inexpensive. And Robert Eckel, a past AHA president who wasn't involved, thinks the benefit likely comes from weight loss, and flags cost and access. Which, for people with prediabetes, usually means no diabetes code and no coverage. If you have prediabetes, this is a reasonable thing to bring to your next appointment, as a question about your options rather than a reason to change what you take.
Emma Kirk, writing for Yahoo News Australia:
A Department of Health spokesman said the TGA approved the registration of a Wegovy oral tablet in 1.5mg, 4mg, 9mg and 25mg strengths.
That's the Therapeutic Goods Administration, Australia's drug regulator, and the news broke there Tuesday. The spokesman said the pill's indications match the injectable Wegovy's. Timing is where the two reports split. Novo said in a statement it expects the pill to be available later this year and will share confirmed timing when it can. Yahoo's piece says it isn't clear when it'll arrive, and that experts expect sometime in 2027. Until now, Wegovy, Ozempic and Mounjaro have only come as injections in Australia. The useful part of this story is actually a GP named Wes Abujalala explaining how the pill works. Stomach acid destroys most of each dose, so only a small fraction gets absorbed. You take it first thing in the morning on an empty stomach with half a cup of water, then wait at least thirty minutes before anything else. He says missing that window, or drinking too much water with it, can cut how much medicine you absorb. And for people with shift work or small kids to handle before breakfast, he suggests the weekly shot may be the more forgiving option. Finally, someone admits a pill isn't automatically easier. For listeners in the U.S., Pharmacy Daily, an Australian trade outlet, notes the pill is already approved here and in Europe. So the takeaway travels: if you're weighing the pill against the injection, talk through your morning routine with your prescriber, not only the price.
Has your state Medicaid program, or your plan, turned you down because the diagnosis on your chart didn't match? We'd like to hear how that played out. Send it to glp1daily at lantern podcasts dot com.
That's the rundown: a coverage barrier Ohio wrote for itself, a promising but preliminary prediabetes signal, and a pill that comes with a strict morning routine. We're a news briefing, not your doctor, so run any of this past the clinician who knows your history. GLP-1 Daily is a Lantern Podcast. We're back Wednesday, November 4.